Health Care [ 6/12 ] | Health Care Providers & Services [ 15/74 ]
NYSE | Common Stock
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally.
The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services.
The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents.
Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | 0.46 Increased by +3.41% | 0.40 Increased by +13.61% |
| Nov 5, 24 | 0.40 Increased by +42.43% | 0.38 Increased by +4.95% |
| Jul 30, 24 | 0.24 Decreased by -20.00% | 0.34 Decreased by -29.41% |
| May 7, 24 | 0.41 Increased by +57.69% | 0.25 Increased by +64.00% |
| Feb 20, 24 | 0.44 Increased by +2.33% | 0.30 Increased by +46.67% |
| Nov 1, 23 | 0.28 Decreased by -30.00% | 0.31 Decreased by -9.68% |
| Aug 2, 23 | 0.30 Decreased by -23.08% | 0.28 Increased by +7.14% |
| May 9, 23 | 0.26 Decreased by -23.53% | 0.12 Increased by +116.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 5.08 B Increased by +1.94% | 66.91 M Decreased by -64.39% | Increased by +1.32% Decreased by -65.07% |
| Sep 30, 24 | 4.76 B Decreased by -3.57% | 213.03 M Increased by +152.55% | Increased by +4.48% Increased by +161.89% |
| Jun 30, 24 | 4.77 B Decreased by -1.22% | 187.00 M Increased by +33.23% | Increased by +3.92% Increased by +34.87% |
| Mar 31, 24 | 4.72 B Increased by +0.44% | 70.96 M Decreased by -46.99% | Increased by +1.50% Decreased by -47.22% |
| Dec 31, 23 | 4.99 B Decreased by -0.18% | 187.93 M Decreased by -3.13% | Increased by +3.77% Decreased by -2.96% |
| Sep 30, 23 | 4.94 B Decreased by -3.14% | 84.35 M Decreased by -63.34% | Increased by +1.71% Decreased by -62.15% |
| Jun 30, 23 | 4.83 B Increased by +1.44% | 140.36 M Decreased by -31.87% | Increased by +2.91% Decreased by -32.83% |
| Mar 31, 23 | 4.70 B Increased by +3.43% | 133.85 M Decreased by -36.80% | Increased by +2.85% Decreased by -38.90% |